Peer-reviewed veterinary case report
Chemotherapy with lomustine and doxorubicin for dog histiocytic
By Cannon, C et al.·Published in The Journal of small animal practice·2015·Veterinary Clinical Sciences Department, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with a serious cancer called histiocytic sarcoma were treated with a combination of two chemotherapy drugs, lomustine and doxorubicin. Out of 17 dogs, 15 had advanced disease, and they received an average of three treatment cycles. About 58% of the dogs showed some improvement, with a median time of about 185 days before the cancer progressed. While many dogs had to stop treatment due to worsening disease, the combination therapy was generally well-tolerated. This approach might be a good option for dogs with this type of cancer.
People also search for: dog histiocytic sarcoma treatment · lomustine and doxorubicin for dogs · chemotherapy side effects in dogs
Abstract
OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25828786/